The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia. Its primary objectives were to answer the following questions:
Which medication is most effective for women with nocturia? Which medication has the least effect on heart rate variability in women with nocturia?
>18 years old.
female patients with overactive bladder syndrome
Clinically significant dysuria (inability to urinate, difficulty urinating).
Severe stress urinary incontinence (urinary incontinence caused by coughing).
Mixed urinary incontinence mainly caused by stress urinary incontinence (urinary incontinence caused by coughing as the main symptom).
Contraindications to antimuscarinic drugs or adrenergic receptor agonists.
Parallel
Mirabegron 25mg
DrugTaking 25 mg mirabegron in the nighttime
Solifenacin 5 mg
DrugTaking 5 mg solifenacin in the nighttime
Tolterodine 4 mg
DrugTaking 5 mg tolterodine in the nighttime
Oxybutynin ER 5 mg
DrugTaking 5 mg oxybutynin ER in the nighttime
Improvement of overactive bladder symptoms
Comparisons of the changes of overactive bladder symptom score between groups
Change of heart rate variability
Comparisons of the changes of heart rate variability between groups
Change of bladder blood perfusion
Comparisons of the changes of bladder blood perfusion between groups
Change of quality of life
Comparisons of the change of King's Health Questionnaire score between groups
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
